Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.070 | Biomarker | disease | BEFREE | FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension. | 29290032 | 2018 | ||||
|
0.070 | AlteredExpression | disease | BEFREE | We determined FoxM1 levels in the lung samples of idiopathic PAH (pulmonary arterial hypertension) (IPAH) patients and hypoxia-induced PH mice. | 30092353 | 2018 | ||||
|
0.070 | AlteredExpression | disease | BEFREE | FoxM1 expression was markedly upregulated in lungs and pulmonary arterial SMCs of patients with idiopathic PAH and four discrete PH rodent models. | 29664678 | 2018 | ||||
|
0.070 | AlteredExpression | disease | BEFREE | The PAH HPASMC exhibit significantly elevated PLK1 and FOXM1 expression and decreased p27 (quiescence protein) levels compared to normal HPASMC. | 31437238 | 2019 | ||||
|
0.070 | Biomarker | disease | BEFREE | BRD4 (bromodomain-containing protein 4), a member of the BET (bromodomain and extra-terminal motif) family, has been identified as a critical epigenetic driver for cardiovascular diseases.<b>Objectives:</b> To explore the therapeutic potential in PAH of RVX208, a clinically available BET inhibitor.<b>Methods:</b> Microvascular endothelial cells, smooth muscle cells isolated from distal pulmonary arteries of patients with PAH, rats with Sugen5416 + hypoxia- or monocrotaline + shunt-induced PAH, and rats with RV pressure overload induced by pulmonary artery banding were treated with RVX208 in three independent laboratories.<b>Measurements and Main Results:</b> BRD4 is upregulated in the remodeled pulmonary vasculature of patients with PAH, where it regulates FoxM1 and PLK1, proteins implicated in the DNA damage response. | 31042405 | 2019 | ||||
|
0.070 | AlteredExpression | disease | BEFREE | A growing number of studies have focused on the relationship between abnormal FOXM1 expression and pulmonary diseases, such as lung cancer, chronic obstructive pulmonary disease (COPD), asthma, acute lung injury (ALI), pulmonary fibrosis, and pulmonary arterial hypertension (PAH). | 30992007 | 2019 | ||||
|
0.070 | Biomarker | disease | BEFREE | FoxM1 has a crucial role in the pathogenesis of pulmonary arterial hypertension and may represent a novel therapeutic target. | 31190319 | 2020 |